Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Sheikh

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
European Radiology|August 25, 2023
Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patientsFreba Grawe, Franziska Blom, Michael Winkelmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2026
PET-based risk stratification for adverse events under [<sup>225</sup>Ac]Ac-PSMA radioligand therapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
European Radiology|March 25, 2023
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patientsFreba Grawe, Ricarda Ebner, Thomas Geyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2025
PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOGErik F Moar, Michael Keilholz, Gabriel T Sheikh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [<sup>225</sup>Ac]Ac-PSMA Radiopharmaceutical TherapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
EJNMMI Research|December 20, 2025
[<sup>18</sup>F]F-FAPI-74 PET/CT for gonadal and extragonadal germ cell Tumors: a pilot studyMarc Kidess, Sophie C Siegmund, Lena M Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 15, 2024
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATE - first clinical experiencesSophie C Kunte, Vera Wenter, Johannes Toms, et al.
EJNMMI Reports|August 18, 2024
PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancerGabriel T Sheikh, Christian Trapp, Nina-Sophie Schmidt-Hegemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2025
[<sup>18</sup>F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paragangliaSophie C Siegmund, Adrien Holzgreve, Magdalena Schöll, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|September 28, 2023
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumorsM P Fabritius, V Soltani, C C Cyran, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
European Radiology|August 25, 2023
Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patientsFreba Grawe, Franziska Blom, Michael Winkelmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2026
PET-based risk stratification for adverse events under [<sup>225</sup>Ac]Ac-PSMA radioligand therapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
European Radiology|March 25, 2023
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patientsFreba Grawe, Ricarda Ebner, Thomas Geyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2025
PSMA PET-Positive Local Recurrences in the Prostate Bed Region and Their Coverage Based on Clinical Target Volume Delineation Guidelines from ESTRO-ACROP, PERYTON, FROGG, GFRU, and RTOGErik F Moar, Michael Keilholz, Gabriel T Sheikh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [<sup>225</sup>Ac]Ac-PSMA Radiopharmaceutical TherapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
EJNMMI Research|December 20, 2025
[<sup>18</sup>F]F-FAPI-74 PET/CT for gonadal and extragonadal germ cell Tumors: a pilot studyMarc Kidess, Sophie C Siegmund, Lena M Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 15, 2024
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATE - first clinical experiencesSophie C Kunte, Vera Wenter, Johannes Toms, et al.
EJNMMI Reports|August 18, 2024
PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancerGabriel T Sheikh, Christian Trapp, Nina-Sophie Schmidt-Hegemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2025
[<sup>18</sup>F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paragangliaSophie C Siegmund, Adrien Holzgreve, Magdalena Schöll, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|September 28, 2023
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumorsM P Fabritius, V Soltani, C C Cyran, et al.
Pageof 6